Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
Year: 2022
Type: article
Study design: Observational Study
Abstract: Background. This manuscript describes the genetic features of SARS‐CoV‐2 mutations, prevalent phylogenetic lineages, and the disease severity amongst COVID‐19‐vaccinated individuals in a tertiary cancer hospital during the second wave of the pandemic in Mumbai, India. Methods. This observational study included 159 COVID‐19 patients during the second wave of the pandemic from 17th March to 1st June 2021 at a tertiary cancer care centre in Mumbai. The cohort comprised of healthcare workers, staff relatives, cancer patients, and patient relatives. For comparison, 700 SARS‐CoV‐2 genomes sequenced during the first wave (23rd April to 25th September 2020) at the same centre were also analysed. Patients were assigned to nonvaccinated (no vaccination or <14 days from the 1st dose, n = 92), dose 1(≥14 days from the 1st dose to <14 days from the 2nd dose, n = 29), and dose 2 (≥14 days from the 2nd dose, n = 38) groups. Primary measure was the prevalence of SARS‐CoV‐2 genomic lineages among different groups. In addition, severity of COVID‐19 was assessed according to clinical and genomic variables. Results. Kappa B.1.1671.1 and delta B.1.617.2 variants contributed to an overwhelming majority of sequenced genomes (unvaccinated: 40/92, 43.5% kappa, 46/92, 50% delta; dose 1: 14/29, 48.3% kappa, 15/29, 51.7% delta; and dose 2: 23/38, 60.5% kappa, 14/38 36.8% delta). The proportion of the kappa and delta variants did not differ significantly across the unvaccinated, dose 1, and dose 2 groups (p = 0.27). There was no occurrence of severe COVID‐19 in the dose 2 group (0/38, 0% vs. 14/121, 11.6%; p = 0.02). SARS‐CoV‐2 genomes from all three severe COVID‐19 patients in the vaccinated group belonged to the delta lineage (3/28, 10.7% vs. 0/39, 0.0%, p = 0.04). Conclusions. Sequencing analysis of SARS‐COV‐2 genomes from Mumbai during the second wave of COVID‐19 suggests the prevalence of the kappa B.1.617.1 and the delta B.1.627.2 variants among both vaccinated and unvaccinated individuals. Continued evaluation of genomic sequencing data from breakthrough COVID‐19 is necessary for monitoring the properties of evolving variants of concern and formulating appropriate immune response boosting and therapeutic strategies.
DOI: 10.1155/2022/2449068
Authors: Arusha Shetty, Gaurav Chatterjee, Sweta Rajpal, Tuhina Srivastava, Nilesh Gardi, Sumeet Mirgh, Anant Gokarn, Sachin Punatar, Nitin Shetty, Amit Joshi, Sudhir Nair, Vedang Murthy, Navin Khattry, Prashant Tembhare, Rajesh Dikshit, Pankaj Chaturvedi, Ashwini More, Sujeet Kamtalwar, Preeti Chavan, Vivek Bhat, Amar Patil, Sachin Dhumal, Prashant Bhat, Papagudi Subramanian, Sumeet Gujral, Rajendra Badwe, Nikhil Patkar, Sudeep Gupta
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,350
OpenAlex ID: W4210968623